CSIMarket
 


Odonate Therapeutics Inc   (ODT)
Other Ticker:  
 

Odonate Therapeutics Inc 's Working Capital Ratio

ODT's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the second quarter 2021, Working Capital Ratio deteriorated to 3.78 above company average Working Capital Ratio.

Within Major Pharmaceutical Preparations industry 8 other companies have achieved higher Working Capital Ratio than Odonate Therapeutics Inc in second quarter 2021. While Working Capital Ratio total ranking has improved so far during the II Quarter 2021 to 680, from total ranking in the first quarter 2021 at 1627.

Explain Working Capital Ratio
How much in Current Assets ODT´s has?
What is the value of ODT´s Current Liabilities?


ODT Working Capital Ratio (Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
(Dec 31 2020)
IV. Quarter
(Sep 30 2020)
III. Quarter
(Jun 30 2020)
II. Quarter
Y / Y Current Liabilities Change 16.02 % 32.15 % 9.26 % 15.22 % 2576.47 %
Y / Y Current Assets Change -12.31 % -13.4 % -13.08 % -8.4 % 67407.91 %
Working Capital Ratio MRQ 3.78 4.11 5.91 6.68 5
ODT's Total Ranking # 680 # 1627 # 279 # 128 # 82
Seq. Current Liabilities Change -10.41 % 22.24 % -5.12 % 11.66 % 2.04 %
Seq. Current Assets Change -17.66 % -14.87 % -16.18 % 49.23 % -18.68 %



Working Capital Ratio second quarter 2021 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 9
Healthcare Sector # 251
Overall Market # 680


Working Capital Ratio Statistics
High Average Low
20.5 3.38 0.11
(Mar 31 2018)   (Jun 30 2012)




Financial Statements
Odonate Therapeutics Inc 's Current Liabilities $ 30 Millions Visit ODT's Balance sheet
Odonate Therapeutics Inc 's Current Assets $ 112 Millions Visit ODT's Balance sheet
Source of ODT's Sales Visit ODT's Sales by Geography


Cumulative Odonate Therapeutics Inc 's Working Capital Ratio

ODT's Working Capital Ratio for the trailling 12 Months

ODT Working Capital Ratio

(Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
(Dec 31 2020)
IV. Quarter
(Sep 30 2020)
III. Quarter
(Jun 30 2020)
II. Quarter
Y / Y Current Liabilities TTM Growth 16.02 % 32.15 % 9.26 % 15.22 % 2576.47 %
Y / Y Current Assets TTM Growth -12.31 % -13.4 % -13.08 % -8.4 % 67407.91 %
Working Capital Ratio TTM 5.06 5.38 5.98 6.35 6.76
Total Ranking TTM # 1191 # 957 # 877 # 663 # 566
Seq. Current Liabilities TTM Growth -10.41 % 22.24 % -5.12 % 11.66 % 2.04 %
Seq. Current Assets TTM Growth -17.66 % -14.87 % -16.18 % 49.23 % -18.68 %


On the trailing twelve months basis Due to fall in Current Liabilities in the II Quarter 2021 to $29.65 millions, cumulative Working Capital Ratio decreased to 5.06 below the Odonate Therapeutics Inc average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 503 other companies have achieved higher Working Capital Ratio than Odonate Therapeutics Inc . While Working Capital Ratio overall ranking has improved so far to 1084, from total ranking during the twelve months ending first quarter 2021 at 1087.

Explain Working Capital Ratio
How much in Current Assets ODT´s has?
What is the value of ODT´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 504
Healthcare Sector # 999
Within the Market # 680


trailing twelve months Working Capital Ratio Statistics
High Average Low
17.27 6.92 0.47
(Mar 31 2018)   (Dec 31 2017)




Companies with similar Working Capital Ratio in the quarter ending Jun 30 2021, within Major Pharmaceutical Preparations Industry Working Capital RatioJun 30 2021 MRQ Current AssetsJun 30 2021 MRQ Current Liabilities
G1 Therapeutics Inc   10.36 $ 265.700  Millions$ 25.641  Millions
Adicet Bio Inc   10.33 $ 216.303  Millions$ 20.947  Millions
Enliven Therapeutics Inc   10.23 $ 71.357  Millions$ 6.973  Millions
Liquidia Corporation  10.23 $ 71.321  Millions$ 6.973  Millions
Ac Immune Sa  10.12 $ 202.634  Millions$ 20.026  Millions
Ngm Biopharmaceuticals Inc   10.06 $ 403.129  Millions$ 40.080  Millions
9 Meters Biopharma Inc   9.80 $ 65.783  Millions$ 6.715  Millions
Sierra Oncology Inc   9.80 $ 92.673  Millions$ 9.461  Millions
Larimar Therapeutics Inc   9.63 $ 74.036  Millions$ 7.691  Millions
Zynerba Pharmaceuticals Inc   9.62 $ 96.455  Millions$ 10.028  Millions
Schrodinger Inc   9.58 $ 649.788  Millions$ 67.858  Millions
Royalty Pharma Plc  9.53 $ 2,707.454  Millions$ 283.989  Millions
Kadmon holdings inc   9.46 $ 286.758  Millions$ 30.318  Millions
Verastem inc   9.46 $ 114.760  Millions$ 12.134  Millions
Arbutus Biopharma Corp  9.44 $ 83.466  Millions$ 8.841  Millions
F star Therapeutics Inc   9.44 $ 85.319  Millions$ 9.041  Millions
Landos Biopharma Inc   9.40 $ 117.727  Millions$ 12.530  Millions
Eton Pharmaceuticals Inc   9.36 $ 29.075  Millions$ 3.106  Millions
Bicycle Therapeutics Plc  9.36 $ 217.788  Millions$ 23.273  Millions
Ocuphire Pharma Inc   9.35 $ 25.240  Millions$ 2.699  Millions
Zai Lab Limited  9.33 $ 1,808.603  Millions$ 193.917  Millions
Carisma Therapeutics Inc   9.30 $ 175.099  Millions$ 18.827  Millions
Guardion Health Sciences Inc   9.17 $ 16.547  Millions$ 1.805  Millions
Aeterna Zentaris Inc   9.12 $ 70.820  Millions$ 7.766  Millions
Acurx Pharmaceuticals inc   9.09 $ 17.440  Millions$ 1.919  Millions
Corcept Therapeutics Inc  9.06 $ 411.270  Millions$ 45.402  Millions
Veru Inc   8.97 $ 154.406  Millions$ 17.212  Millions
Neurobo Pharmaceuticals Inc   8.85 $ 10.468  Millions$ 1.183  Millions
Foghorn Therapeutics Inc   8.81 $ 144.672  Millions$ 16.414  Millions
Protagonist Therapeutics inc   8.65 $ 371.818  Millions$ 42.973  Millions

Date modified: -0001-11-30T00:00:00+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com